SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 16, 1995
ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)
Massachusetts 0-17999 04-2726691
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
128 Sidney Street, Cambridge, Massachusetts 02139
Registrant's telephone number, including area code:(617) 661-9312
Page 1 of 5 pages
Item 5. Other Events.
On August 17, 1995, the Registrant publicly disseminated a press release
announcing that the Registrant issued $3.6 million of subordinated,
convertible debentures pursuant to Regulation S of the Securities Act of
1933. The information contained in the press release is incorporated herein
by reference and filed as Exhibit 99.1 hereto.
Item 7. Financial Statements and Exhibits.
(c) Exhibits.
99.1 The Registrant's Press Release dated August 17, 1995.
Page 2 of 5 pages
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ImmunoGen, Inc.
(Registrant)
Date: August 29, 1995 /s/Frank J. Pocher
Frank J. Pocher
Vice President and
principal financial officer
Page 3 of 5 pages
EXHIBIT INDEX
Exhibit Sequential
Number Description Page Number
99.1 The Registrant's Press 5
Release dated August 17, 1995.
Page 4 of 5 pages
contact: Mitchel Sayare
Chairman, Chief Executive Officer
617-661-9312
FOR IMMEDIATE RELEASE
IMMUNOGEN ISSUES $3.6 MILLION OF CONVERTIBLE DEBENTURES
Cambridge, Mass., August 17, 1995--ImmunoGen, Inc. (Nasdaq: IMGN) today
announced that it has completed the sale of $3.6 million of subordinated,
convertible debentures to a small number of European investors. The
transaction was undertaken pursuant to Regulation S of the Securities Act of
1933.
"This transaction provides timely financial support for the company," states
Chairman and Chief Executive Officer, Mitchel Sayare. "Since the
registration of patients to our Phase III study of Oncolysin B has taken
longer than we expected, these funds buy us more time to evaluate how to boost
the accrual rate. In addition we also are evaluating other options that could
shorten the time to complete the clinical trial, though we will need to raise
additional funds before these studies are completed."
The terms of the transaction allow the investors to convert the debentures to
shares of ImmunoGen common stock during the period beginning October 2, 1995
through July 31, 1996. The conversion price is based on a pre-determined
discount to the market price at the time of conversion.
ImmunoGen, Inc. develops innovative biopharmaceuticals, primarily for the
treatment of cancer. The company has created potent immunoconjugates,
consisting of toxins or drugs coupled to monoclonal antibodies for delivery to
and destruction of cancer cells at specific stages of disease.
###
Page 5 of 5 pages
